Michele Maio
About
Michele Maio is a scholar working on Oncology, Molecular Biology and Immunology.
According to data from OpenAlex, Michele Maio has authored 376 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Oncology, 143 papers in Molecular Biology and 143 papers in Immunology. Recurrent topics in Michele Maio's work include Cancer Immunotherapy and Biomarkers (158 papers), Immunotherapy and Immune Responses (120 papers) and CAR-T cell therapy research (102 papers). Michele Maio is often cited by papers focused on Cancer Immunotherapy and Biomarkers (158 papers), Immunotherapy and Immune Responses (120 papers) and CAR-T cell therapy research (102 papers). Michele Maio collaborates with scholars based in Italy, United States and France. Michele Maio's co-authors include Maresa Altomonte, Ester Fonsatti, Jedd D. Wolchok, Anna Maria Di Giacomo, Luca Sigalotti, Célèste Lebbé, Omid Hamid, Luana Calabrò, Jeffrey S. Weber and Sandra Coral and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Communications.
In The Last Decade
Michele Maio
367 papers receiving 18.1k citations
Hit Papers
Peers
Michele Maio
Mario Sznol United States
Patrick Hwu United States
Ulrich Keilholz Germany
Daniel S. Chen United States
Richard M. Sherry United States
John Nemunaitis United States
Paul B. Chapman United States
John B.A.G. Haanen Netherlands
Achim A. Jungbluth United States
Christian U. Blank Netherlands
Citations per year, relative to Michele Maio Michele Maio (= 1×)
peers
Mario Sznol
Countries citing papers authored by Michele Maio
Since
Specialization
Citations
This map shows the geographic impact of Michele Maio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Maio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Maio more than expected).
Fields of papers citing papers by Michele Maio
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michele Maio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Maio. The network helps show where Michele Maio may publish in the future.
Co-authorship network of co-authors of Michele Maio
This figure shows the co-authorship network connecting the top 25 collaborators of Michele Maio. A scholar is included among the top collaborators of Michele Maio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Maio. Michele Maio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Caruso, Francesca Pia, Teresa Noviello, Roberta Mortarini, et al.. (2025). DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. Journal of Experimental & Clinical Cancer Research. 44(1). 58–58.
2.
Subudhi, Sumit K., Wim Vos, Massimo Andreatta, et al.. (2025). Perspectives on the role of “-Omics” in predicting response to immunotherapy. European Journal of Cancer. 220. 115393–115393.
3.
Silva, Inês Pires da, Lisa Zimmer, Jean‐Yves Blay, et al.. (2025). Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open. 10(11). 105833–105833.
4.
Majem, Margarita, Vanesa Gregorc, Giuseppe Lo Russo, et al.. (2025). LBA1: First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 20(3). S1–S1.
5.
Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511.
6.
Rodríguez‐Abreu, Delvys, Byoung Chul Cho, Tibor Csőszi, et al.. (2024). Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC). Cancer Research. 84(7_Supplement). CT253–CT253.
7.
Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654.
8.
Lipson, Evan J., Sonia Dolfi, Hao Tang, et al.. (2023). LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047. Annals of Oncology. 34. S1290–S1291.
9.
Noviello, Teresa, Anna Maria Di Giacomo, Francesca Pia Caruso, et al.. (2023). Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nature Communications. 14(1). 5914–5914.
10.
Miracco, Clelia, et al.. (2022). Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”. OncoTargets and Therapy. Volume 15. 1409–1415.
11.
Spada, Francesca, Paolo Bossi, Corrado Caracò, et al.. (2022). Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. Journal for ImmunoTherapy of Cancer. 10(6). e004742–e004742.
12.
Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745.
13.
Ascierto, Paolo A., Brigitte Dréno, James Larkin, et al.. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research. 27(19). 5225–5235.
14.
Eggermont, Alexander M.M., Vanna Chiarion‐Sileni, Jean-Jacques Grob, et al.. (2019). Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer. 119. 1–10.
15.
Yan, Yibing, Matthew Wongchenko, Caroline Robert, et al.. (2019). Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic Melanoma. Clinical Cancer Research. 25(11). 3239–3246.
16.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936.
17.
Zelba, Henning, Benjamin Weide, Alexander Martens, et al.. (2014). Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research. 20(16). 4390–4399.
18.
Weide, Benjamin, Alexander Martens, Henning Zelba, et al.. (2013). Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells. Clinical Cancer Research. 20(6). 1601–1609.
19.
Sabatino, Marianna, Yingdong Zhao, Sonia Voiculescu, et al.. (2008). Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis. Cancer Research. 68(1). 122–131.
20.
Maio, Michele, Maresa Altomonte, Revati J. Tatake, R A Zeff, & Soldano Ferrone. (1991). Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.. Journal of Clinical Investigation. 88(1). 282–289.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Patrick Hwu Breakdown of academic impact, for papers by Ulrich Keilholz Breakdown of academic impact, for papers by Daniel S. Chen Breakdown of academic impact, for papers by Richard M. Sherry Breakdown of academic impact, for papers by John Nemunaitis Breakdown of academic impact, for papers by Paul B. Chapman Breakdown of academic impact, for papers by John B.A.G. Haanen Breakdown of academic impact, for papers by Achim A. Jungbluth Breakdown of academic impact, for papers by Christian U. Blank